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In vitro analysis of natural product biosynthetic
gene products isolated from unculturable symbiotic
bacteria is necessary to probe the functionalities of
these enzymes. Herein, we report the biochemical
characterization of BryR, the 3-hydroxy-3-methylglu-
taryl (HMG)-CoA synthase (HMGS) homolog impli-
cated in b-branching at C13 and C21 of the core
ring system from the bryostatin metabolic pathway
(Bry). We confirmed the activity of BryR using two
complementary methods, radio-SDS PAGE, and
Fourier transform ion cyclotron resonance-mass
spectrometry (FTICR-MS). The activity of BryR
depended on pairing of the native acetoacetyl-
BryM3 acceptor acyl carrier protein (ACP) with an
appropriate donor acetyl-ACP from a heterologous
HMGS cassette. Additionally, the ability of BryR to
discriminate between various ACPs was assessed
using a surface plasmon resonance (SPR)-based
protein-protein binding assay. Our data suggest
that specificity for a protein-bound acyl group is
a distinguishing feature between HMGS homologs
found in PKS or PKS/NRPS biosynthetic pathways
and those of primary metabolism. These findings
reveal an important example of molecular recogni-
tion between protein components that are essential
for biosynthetic fidelity in natural product assembly
and modification.
INTRODUCTION
The bryostatins are antifeedant polyketide natural products
produced by a bacterial symbiont of themarine bryozoanBugula
neritina (Sudek et al., 2007). They are highly potent protein kinase
C (PKC) modulators (Nelson and Alkon, 2009), and, as such,
bryostatin 1 (Figure 1) has been investigated in numerous clinical
trials as a potential anticancer agent (Banarjee et al., 2008).1092 Chemistry & Biology 17, 1092–1100, October 29, 2010 ª2010 ESeparately, the neuroprotective activity of PKC activators has
recently been demonstrated in preclinical studies where bryo-
statin 1 was able to rescue memory loss after postischemic
stroke (Sun et al., 2009). Additional studies suggest that bryo-
statin 1 (and a synthetic analog) may be able to reduce the levels
of Ab, a toxic peptide implicated in Alzheimer’s disease (Khan
et al., 2009; Nelson et al., 2009). However, like many marine-
derived natural products, fulfilling the promise of these initial
studies may be hindered by the low abundance of bryostatins
available from either natural sources or chemical synthesis
(Sudek et al., 2007; Singh et al., 2008). The intriguing biological
activities and lingering supply questions motivate our continued
study of the bryostatin biosynthetic pathway (Figure 1). Increas-
ing our knowledge of the molecular mechanisms employed may
help open the door to new methods of bryostatin production as
well as the generation of related bryostatin analogs. Herein, we
report the biochemical characterization of BryR, the 3-hydroxy-
3-methylglutaryl (HMG)-CoA synthase (HMGS) homolog impli-
cated in b-branching at C13 and C21 of the core bryostatin
ring system (Figures 1 and 2).
Polyketide metabolites are produced by diverse bacterial
taxa, including soil-dwelling bacteria, cyanobacteria, and bacte-
rial symbionts living within insects or marine invertebrates, and
are all generated by decarboxylative condensation reactions of
simple coenzyme A (CoA) building blocks (Staunton and Weiss-
man, 2001; Weissman, 2009; Hertweck, 2009). Polyketides with
variable levels of reduction at the b-ketone position are built by
type I polyketide synthases (PKSs). Type I PKSs are composed
of a linear arrangement of covalently fused catalytic domains
within large, multifunctional proteins. A unidirectional assembly
line process is used to generate a linear intermediate that is often
off-loaded as a cyclized lactone product. Sets of domains
grouped together to accomplish a single round of extension
are termed modules. The number, arrangement, and architec-
ture of modules within type I systems serve as a blueprint to
determine the core structure of the natural product (Weissman,
2009; Smith and Tsai, 2007; Fischbach and Walsh, 2006).
While methylation at the a position relative to the carbonyl
group is well characterized (Staunton and Weissman, 2001;
Smith and Tsai, 2007), alkylation at the b position (e.g., b-branch-
ing) is less commonly observed but can introduce furtherlsevier Ltd All rights reserved
Figure 1. Portions of the Pathway Utilized in b-Branching Are Highlightedwith Color in this Depiction of the Bryostatin Biosynthetic Pathway
BryC, BryX, and BryD are not shown (Sudek et al., 2007). Though the complete structure of the PKC modulator bryostatin 1 is shown here, the full suite
of bryostatin molecules contains acyl chain variability at both C7 and C20. ACP, acyl carrier protein; AT, acyltransferase; DH, dehydratase; FkbH, homolog
to FkbH (Wu et al., 2000); HMGS, HMG-CoA synthase homolog; KR, ketoreductase; KS, ketosynthase; KSDC, decarboxylative ketosynthase; MT, methyltrans-
ferase; Unk, domain with unknown function. Refer to Figure S1 for more information.
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and biochemical evidence has been obtained to demonstrate
that b position alkyl side chains are typically introduced through
an ‘‘HMGS cassette’’ of enzymes/domains performing reactions
similar to those observed inmevalonate biosynthesis (Figures 2A
and 2B) (Calderone et al., 2006, 2008; Geders et al., 2007; Gu
et al., 2006; Simunovic and Mu¨ller, 2007a, 2007b). This set of
enzymes typically contains three discrete proteins; the HMGS
homolog, a decarboxylative ketosynthase (Cys to Ser active
site variant, KSDC), and a donor acyl carrier protein (ACPD)
upon which acetyl-ACPD (Ac-ACPD) is typically generated. Addi-
tionally, one or two enoyl-CoA hydratase (ECH) homologs
responsible for dehydration and decarboxylation transforma-
tions (ECH1 and ECH2, respectively) may be present as discrete
proteins or embedded domains in larger, multifunctional proteins
(Figure 2B; see Figure S1 available online). Finally, many of the
pathways contain tandem acceptor ACPs (ACPA) at the site of
modification. Full HMGS cassettes have been shown to install
methyl branch points in bacillaene, curacin, jamaicamide, and
mupirocin (Geders et al., 2007; Gu et al., 2006; Calderone
et al., 2006; Wu et al., 2007), and hypothesized for methylationChemistry & Biology 17, 1092–1in pederin (Piel et al., 2004), and virginiamycin M (Pulsawat
et al., 2007). Methoxymethyl and ethyl branches are added to
the growing myxovirescin molecule in a similar fashion (Simu-
novic and Mu¨ller, 2007b; Calderone et al., 2007). However, the
identity of the AT/KS pair responsible for generating the pro-
pionyl-ACPD remains unconfirmed (Liu et al., 2009). In some
cases, the methyl branch points are elaborated further by neigh-
boring domains (the action of the nearby halogenase and enoyl
reductase domains convert the b position in the mature curacin
to a cyclopropyl ring while jamaicamide contains a vinyl chloride)
(Gu et al., 2009; Figure S1). One notable exception to the HMGS-
mediated chain-branching strategy was recently found in the rhi-
zoxin biosynthetic pathway where a PKS-mediated Michael
addition is employed in the generation of a d-lactone (Kusebauch
et al., 2009).
Partial HMGS cassettes have been identified in the onnamide,
difficidin, psymberin, leinamycin (Piel et al., 2004; Liu et al., 2009;
Chen et al., 2006; Fisch et al., 2009), and bryostatin (missing
ACPD, ECH1 & ECH2) (Sudek et al., 2007) biosynthetic pathways
(Figure S1). Lack of complete gene cluster sequencing or anno-
tation is one possible explanation for the presence of a partial100, October 29, 2010 ª2010 Elsevier Ltd All rights reserved 1093
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Figure 2. Proteins and/or Domains Involved
in HMG Generation
(A and B) (A) HMG generation in the mevalonate
pathway and (B) during polyketide b-branching in
PKS and mixed biosynthetic pathways. The cova-
lent, enzyme-bound intermediate from the reaction
being analyzed in this paper is boxed.
(C) The HMGS cassette ACPD subclass of acyl
carrier proteins can be observed in the phyloge-
netic tree generated using Jalview software
(average distance BIOSUM2) (Clamp et al., 2004).
Refer to Figure S2 for more information.
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virginiamycin, difficidin, and bryostatin systems where bound-
aries have yet to be determined for contiguous pathways
or the pathway is possibly dispersed across the genome.
In other instances (leinamycin, bryostatin), product formation
is unlikely to involve enzymatic transformations by the ECH
homologs (dehydration and decarboxylation). Alternately, func-
tions performed by the canonical set of HMGS cassette
members might be catalyzed by alternative domains/enzymes
within the pathway. For example, the leinamycin pathway
does not include a KSDC, as LnmK fulfills this role as an acyl-1094 Chemistry & Biology 17, 1092–1100, October 29, 2010 ª2010 Elsevier Ltd All rights restransferase/decarboxylase to generate
the acyl donor propionyl-LnmL (Liu
et al., 2009). Similarly, the b-methoxylacy-
lidene moieties found in the bryostatins
are hypothesized to be the result of a
b-g dehydration (whereas the dehydra-
tion performed by ECH1 enzymes
typically occurs across the a-b positions)
(Calderone, 2008). The N-terminal
domains of unknown function found on
BryB and BryC are candidates to catalyze
these transformations, found immediately
downstream of both HMGS modification
sites in the bryostatin pathway (Sudek
et al., 2007).
The type I PKS biosynthetic gene
cluster (bry) presumed responsible for
the synthesis of the bryostatins has been
identified and sequenced from two sibling
unculturable bacterial symbiont species
of ‘‘Ca. Endobugula sertula/B. neritina’’
(Sudek et al., 2007). The shallow-water
North Carolina (NC) sibling species
appears to be located within a contiguous
DNA fragment approximately 77 kb in
length, whereas the deep-water California
(CA) species is split between two or more
locations on the chromosome. Apart from
the transposition of the HMGS cassette
and AT enzymes, the two sequences
exhibit >99.5% identity at the DNA level.
In the current study, we have focused
on BryR from the NC species of ‘‘Ca.
Endobugula sertula/B. neritina’’ to eluci-date its role in the b-branching process (e.g., formation of
HMG-ACP) during bryostatin assembly.
The canonical HMGS cassette activities have been elucidated
through in vitro biochemistry or in vivo gene disruption studies in
the bacillaene, curacin/jamaicamide, and myxovirescin path-
ways (Calderone, 2008). A key step for selectivity in the HMGS
cassette appears to be the HMGS reaction itself (Calderone
et al., 2006). Biochemical studies of PksG, the HMGS homolog
of the bacillaene pathway, revealed that the enzyme only
accepts the acetyl group when presented on AcpK, its cognate
ACPD (Calderone et al., 2006). In addition, gene deletion studieserved
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two HMGS homologs present (TaC/TaF) utilize separate ACPDs
(TaB/TaE) (Simunovic and Mu¨ller, 2007a). The ability of PksG to
accept a model substrate, acetoacetyl (Acac)-ACPA, is consis-
tent with the importance of protein-protein interactions for
HMGS-ACPD specificity (Calderone et al., 2006). The role of
protein-protein interactions in mediating biosynthetic processes
for polyketide b-branching, and its role in chemical diversifica-
tion motivated our current studies, described below.
RESULTS AND DISCUSSION
Based on the reported activities of the previously characterized
secondary metabolite HMGS homologs PksG and TaC (Calder-
one et al., 2006, 2007), BryR is likely to be involved in the b-
branching at C13 and C21 of the bryostatins (Figures 1 and 2).
To date, no discrete ACP for theHMGScassette of the bryostatin
pathway has been located in either the NC or CA bry cluster
sequences. The possibility exists that BryR, like its primary
metabolism counterparts, may be able to use acetyl-CoA as
the acyl donor in its reaction (Calderone, 2008). However, the
presence of a KS-type (BryQ) decarboxylase, whose presumed
role is to generate acetyl-ACP from malonyl-ACP, makes this
an unlikely scenario. A discrete ACP upstream of the bry cluster
was identified adjacent to genes that encode proteins likely
involved in fatty acid biosynthesis (Bry FAS ACP). Though other
fatty acid synthase (FAS) ACPs have not been reported as part of
HMGS cassettes, no other endogenous ACPD candidates were
evident in or near the bry cluster. Therefore, in the absence of
a Bry ACPD, we sought to identify surrogate acetyl donors for
substrate loading of BryR.
Several types of ACPs were surveyed (discrete ACPDs from
HMGS-cassettes, type II PKSs and bacterial FASs, and excised
ACPs from type I PKSs) in search of suitable ACPD partners
for BryR (Figure 2C). The unmodified (apo-) and phosphopante-
theine (PPant)-containing (holo-) forms of the ACPs were
overexpressed in Escherichia coli and purified. The Ac- or
Acac-modified ACPs were generated by loading the apo-ACPs
in vitro using Sfp or Svp (flexible phosphopantetheinyl transfer-
ases [PPTases], respectively) (Lambalot et al., 1996; Sanchez
et al., 2001). Modified ACPs were separated from unreacted
CoAs before testing (see Supplemental Information). To assess
the ability of BryR to catalyze HMG formation using the surrogate
acyl carriers (Ac-ACPD + Acac-ACPA/ HMG-ACPA), we moni-
tored the enzymatic activity of BryR when paired with different
Ac-ACPD and Acac-ACPA substrates.
In primarymetabolism, HMG-CoA synthase (HMGS) catalyzes
the condensation of C2 of acetyl-CoA onto the b-ketone of ace-
toacetyl-CoA to form 3-hydroxyl-3-methylglutaryl-CoA and free
CoASH (Lange et al., 2000; Steussy et al., 2005, 2006). A number
of secondary metabolite pathways have been identified over the
past 5 years that perform a similar reaction, although they appear
to use ACP-tethered acyl groups as opposed to acyl-CoA
substrates. By analogy to primary metabolism HMGSs, the first
step in the BryR mechanism should be acetylation of the active
site cysteine in the enzyme (Theisen et al., 2004). Subsequently,
the C2 of acetate reacts with the b-keto group of the Acac-ACPA
substrate to form HMG (or a related molecule during biosyn-
thesis) (Figures 2A and 2B). These steps were assessed byChemistry & Biology 17, 1092–1both Fourier transform ion cyclotron resonance mass spectrom-
etry (FTICR-MS) (Figure 3A) and radio-SDS PAGE (Figure 3B).
Substrate transfer from Ac-ACP (FTICR-MS) or [1-14C]-Ac-
ACP (radio-SDS PAGE) to BryR was confirmed only when
a member of the discrete HMGS-cassette ACPD group (Fig-
ure 2C) was paired with BryR (Figure 3). By FTICR-MS, we
were also able to observe loss of the Ac-ACPD species and its
conversion to holo-ACPD in the presence of BryR (Figure 3A;
Figures S4–S7).
Generation of the Ac-BryR intermediate during the first half of
the reaction can be visualized in the phosphorimage only when
[1-14C]-Ac-CurB (HMGS-cassette ACPD) donates the acetyl
group (Figure 3B). To confirm that the BryR reaction proceeds
through the same enzyme intermediate as those observed in
primary metabolism, we confirmed that the acetylation occurs
on Cys114. BryR (10 mM) was reacted with Ac-MacpC (50 mM)
in the absence of an ACPA. After the sample was proteolyzed
with trypsin, peptides were separated by HPLC, and using
LC-FTICR MS and ion trap LC-MS/MS the BryR active site
peptide was identified and acetylation of Cys114 was confirmed
(Table 1). Additionally, a mutant form of the protein at this loca-
tion (C114A) was enzymatically inactive (data not shown). These
data represent the first direct demonstration of the Ac-Cys
species in an HMGS homolog in polyketide biosynthesis.
As evidence of the ability of BryR to catalyze the complete
reaction (Ac-ACPD + Acac-ACPA/ HMG-ACPA), we observed
a third radioactive band, consistent with modification of BryM3
ACP (a model acceptor substrate), an embedded ACP excised
from the BryA tetramodule at one of the predicted HMGS modi-
fication sites (Figures 1 and 3B). To identify the chemical modifi-
cation on BryM3 ACP, the reaction mixtures were monitored by
top-down FTICR-MS. The mass shift of +60.0 Da on the intact
BryM3 ACP between the +/ BryR samples is consistent with
conversion of the Acac-BryM3 ACPA substrate to HMG-BryM3
ACPA (Figure 3A). MS/MS analysis was performed using the
PPant ejection assay (Dorrestein et al., 2006a, 2006b), which
confirmed that the mass shift between +/ BryR samples is
due to modification of the PPant prosthetic group. No product
formation was observed when Ac-Bry FAS ACP was incubated
with BryR and Acac-BryM3 ACP (data not shown). Other reac-
tions without detectable product formation included an Ac-FAS
ACP donor from Streptomyces coelicolor (SCO2389, Sc FAS
ACP) (Arthur et al., 2009), an Ac-CoA donor, using BryM3 ACP
as both donor and acceptor, or Acac-FAS ACPs or Acac-MacpC
as acceptors (data not shown).
Since the HMGS homologs found in secondarymetabolism do
exhibit a preference for acyl-ACPs, we sought to measure the
affinity of BryR for these ACPs. The direct binding of BryR to
a variety of potential Ac-ACPDs as well as the model acetoacetyl
acceptor substrate, Acac-BryM3 ACP was assessed (Figure 4).
After BryR immobilization to a BIAcore CM5 SPR chip
(Figure S10), equilibrium binding analysis was performed using
sequential injections of apo-, holo-, Ac-, or Acac-ACPs at
varying concentrations (Figure 4; Figure S11). Active BryR (WT)
and an enzymatically inactive (C114A) BryR mutant behaved
similarly in our binding studies. BryR was able to bind to ACPDs
from the curacin (CurB), jamaicamide (JamF), and mupirocin
(MacpC) HMGS cassettes as well as to the excised native
acceptor (BryM3 ACP) (Figure S1). Affinities (KDs) were in the100, October 29, 2010 ª2010 Elsevier Ltd All rights reserved 1095
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Figure 3. BryR Catalyzed Generation of HMG-BryM3 ACP from Ac-MacpC
(A) As monitored by FTICR-MS, data are presented as m/z (x-axis) versus abundance (y-axis). PPant ejection assay data from the entire charge state distribution
are presented. PPant ejection peaks are in the +1 charge state. Intact donor and acceptor ACP data are also illustrated. Holo- and Ac-MacpC peaks are shown in
the +13 charge state. Acac- and HMG-BryM3 are shown in the +14 charge state. Particular charge states illustrated are representative of the entire charge state
envelope.
(B) Rado-TLC monitored acetyl transfer from [1-14C]-Ac-CurB to Acac-BryM3 ACP to form HMG-BryM3 ACP monitored by radio-SDS PAGE.
Refer to Figures S4–S9 for more information.
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Table 1. Ac-BryR Active Site Peptide Fragment Ions Observed in
Ion Trap LC/MS/MS
Mass Intensity IDa Dppm
480.18 62 a4 28
463.13 30 a4 - NH3 65
567.19 18 a5 67
550.24 28 a5 - NH3 79
708.28 76 a7 - NH3 19
753.19 51 b7 132
735.22 451 b7 - H2O 76
736.23 145 b7 - NH3 37
824.28 22 b8 53
806.54 16 b8 - H2O 276
807.32 91 b8 - NH3 28
732.35 17 y6 - NH3 70
749.30 21 y6 - NH3 171
845.34 20 y7 - NH3 172
1,064.52 18 y9 63
1,047.46 35 y9 - NH3 104
ab- and y-type fragment ions originate from peptide backbone bond
cleavage where b ions contain the peptide N terminus and y ions contain
the peptide C terminus. The subscripted number indicates the number of
amino acid residues in a particular fragment. a-type ions result from
secondary fragmentation of b ions via CO loss.
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ACPA (180 mM). The pattern of BryR binding affinities correlated
well with that observed in our enzymatic activity assays.
No significant binding was observed between Bry FAS ACP
(up to 500 mM) or Sc FAS ACP (up to 650 mM) and BryR
(Figure 4B). No enhancement of affinity was observed between
apo- and Ac-ACPD or between apo-, holo-, Ac-, AcAc-, or
HMG-ACPA (Figure 4B). Thus, the affinity of BryR for the ACPs
seems to be mediated mainly by protein-protein contacts (as
opposed to protein-acyl chain or protein-PPant contacts). These
data suggest that specificity for a protein-bound acyl group is
a distinguishing feature between HMGS homologs found in
PKS or mixed PKS/nonribosomal peptide synthase (NRPS)
biosynthetic pathways and those of primary metabolism.
SIGNIFICANCE
We have investigated the enzymatic function of BryR
(condensation of acetyl-ACPD with acetoacetyl-ACPA to
form HMG-ACPA) using two complementary methods,
radio-SDS PAGE and FTICR-MS. The activity of BryR was
dependent on pairing of the native Acac-BryM3 acceptor
ACP with an appropriate surrogate Ac-ACPD from a related
HMGS cassette (CurB, JamF, or MacpC). In addition, the
ability of BryR to discriminate between various ACPs was
assessed using an SPR-based protein-protein bindingChemistry & Biology 17, 1092–1assay. BryR bound selectively to ACPs obtained from
a series of HMGS cassettes (MacpC, CurB, JamF, and
BryM3 ACP). To date, no structural insights have been
reported for the interaction of HMGS cassette enzymes
with partner ACPDs. These future studies will be essential
to determine the nature of BryR’s ACP binding selectivity.
Finally, this work, as well as other recent studies (Fisch
et al., 2009; Lopanik et al., 2008) demonstrates further that
natural product biosynthetic genes isolated from uncultura-
ble marine symbiotic bacteria can be manipulated in vitro in
order to probe the functionalities of these enzymes from
previously inaccessible sources.
EXPERIMENTAL PROCEDURES
Expression and Purification of Proteins
Plasmids encoding N-terminal His6- or His6/MBP- fusion protein tags were
transformed into E. coli BL21(DE3) and grown at 37C in TB medium to an
OD600 of1.0 in 2 liter flasks. The cultures were cooled to 18C, and isopropyl
b-D-thiogalactopyranoside was added to a final concentration of 0.2 mM and
grown 12–16 hr with shaking. The cells were harvested by centrifugation and
frozen at 20C. Cell pellets were thawed to 4C and resuspended in 5X
volume of lysis buffer (20mMHEPES [pH 7.8], 300mMNaCl, 20mM imidazole,
1 mM MgCl2, 0.7 mM Tris [2-carboxyethyl] phosphine [TCEP], 100 mg
CelLytic Express [Sigma-Aldrich]) before lysis via sonication. Centrifugation
at 25,0003 g for 30min provided clarified lysates. Proteins were purified using
Ni-Sepharose affinity chromatography on an Akta FPLC. In brief, after filtration
of the supernatant through 0.45 mm membrane, the solution was loaded onto
a 5ml HisTrap nickel-nitrilotriacetic acid column. The columnwaswashedwith
ten column volumes of buffer A (20 mMHEPES [pH 7.8], 300mMNaCl, 20 mM
imidazole, 0.7 mM TCEP) and eluted with a linear gradient of buffer B (20 mM
HEPES [pH 7.8], 300 mM NaCl, 400 mM imidazole, 0.7 mM TCEP). For ACP
purifications, fractions were pooled, concentrated, and loaded onto a HiLoad
16/60 Superdex 75 (GE Healthcare Life Sciences) column equilibrated with
storage buffer (20 mM HEPES [pH 7.4], 150 mM NaCl, 0.7 mM TCEP). Frac-
tions were combined, concentrated, frozen, and stored at 80C. Because
some of the acyl carrier proteins lack amino acids with appreciable absor-
bance at 280 nm, protein concentrations were determined via the bicincho-
ninic acid (BCA) method using BSA as a standard. BryR purifications differed
from ACP purifications in that all buffers contained 10% glycerol in addition to
the components listed above. In addition, for SPR and FTICR-MS assays, His-
MBP-tag removal was achieved by TEV protease incubation overnight at 4C
in buffer A. TEV protease and the N-terminal His-MBP tag were removed by
repassaging the solution over the HisTrap column. Flow-through fractions
were pooled, concentrated, and loaded onto a HiLoad 16/60 Superdex 200
column equilibrated with BryR storage buffer (10% glycerol, 20 mM HEPES
[pH 7.4], 150 mM NaCl, 0.7 mM TCEP). Fractions were combined, concen-
trated, frozen, and stored at 80C. Protein concentrations were determined
using absorbance at 280 nm and calculated extinction coefficients (1 A280 =
1.2mg/ml). ACPs were greater than 95%pure following the above purification.
Typical yields for BryR batches were 3 mg/liter of cell culture. TEV-cleaved
BryR was approximately 85%–90% pure. Purity estimates are based on
SDS-PAGE (Figure S3).
Enzymatic Analysis of BryR via Radio-TLC
Radiolabeled and unlabeled acyl-CoA substrates were transferred onto the
various ACPs using Svp, a phosphopantheine transferase (PPTase) from
Streptomyces verticillus (Sanchez et al., 2001). Acyl-CoAs (500 mM) were
combined with 75 mM ACPs (CurB, BryM3 ACP) and 5 mM Svp in a Tris buffer
(pH 7.4) containing MgCl2 (10 mM) and DTE (1 mM), and the reaction
proceeded for 1 hr at room temperature. The substrate-bound ACPs were
desalted and utilized for experiments with BryR. The purified acylated donor
(15 mM) and acceptor ACPs (30 mM) were incubated with BryR (10 mM) in
25 mM Tris buffer (pH 7.4) with DTE (1 mM) at room temperature for 5 min.
Reactions were quenched by the addition of SDS-PAGE gel loading buffer.
Samples were separated on polyacrylamide gels by SDS-PAGE. The gels100, October 29, 2010 ª2010 Elsevier Ltd All rights reserved 1097
AB
Figure 4. Binding of apo-ACPs to Immobi-
lized BryR, Monitored by SPR
(A) Each data point is the average of triplicate
measurements; error bars are standard deviation.
The data were fit to a one-site binding model
(Y = Bmax*X/(KD + X)). Y = fraction bound, Bmax =
maximal response, X = ACP concentration.
Dissociation constants (KDs) are reported in (B).
Forms of ACPs shaded gray in the table were
not tested. Refer to Figures S10 and S11 for
more information.
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Phosphoimager screens. The screenswere scanned using a Typhoon Scanner
(GE Healthcare) and analyzed using ImageQuant.
Enzymatic Analysis of BryR via FTICR-MS
The preparation of acetyl-donor and acetoacetyl-acceptor ACPs was per-
formed as above using Svp or Sfp PPTases(Lambalot et al., 1996). Acylated-
ACPs were separated from CoA substrates via Zeba desalting columns
(Pierce) or overnight dialysis in 3.5 kDa Slide-a-lyzer MINI dialysis units (Pierce)
into 20 mM HEPES (pH 7), 150 mM NaCl. BryR (10 mM) was reacted with
acetyl-donor ACP (50 mM) and acetoacetyl-acceptor ACP (80 mM) 75 mM
HEPES (pH 7.5) buffer and 1 mM TCEP. After incubation for 60 min at room
temperature, samples were acidified with 1% formic acid. Intact protein
samples were desalted with Handee Microspin columns (Pierce) packed
with 20 ml of 300 A˚ polymeric C4 resin (Vydac). Samples were loaded onto
the columns and washed with 30 column volumes of 0.1% formic acid prior
to elution with 10 column volumes of 50% acetonitrile plus 0.1% formic
acid. Intact protein samples were analyzed by an FTICR MS (APEX-Q with
Apollo II ion source and actively shielded 7T magnet; Bruker Daltonics). Data
were gathered from m/z 200–2000 utilizing direct infusion electrospray ioniza-
tion in positive ion mode. Electrospray was conducted at 3600 V with 24–60
scans per spectrum utilizing 0.5 s external ion accumulation in a hexapole
and 15 ICR cell fills prior to excitation and detection. Collision cell pressure
was reduced to 2.5e-6 Torr for improved transmission of protein ions. Infrared
multiphoton dissociation (IRMPD) MS/MS was performed in the FTICR cell.
This approach is preferred over external collision induced dissociation,
because time-of-flight effects during ion transport into the FTICR cell are
avoided. The laser power was 10 W with an irradiation time of 0.05–0.25 s.
The entire mass range was fragmented, without any prior mass selection.
Data were processed in Data Analysis (Bruker Daltonics) and Midas (NHMFL).
All mass shifts shown were confirmed across all charge states for each ACP
present. An abundant charge state is used for Figure 3 and Figures S4–S9 illus-
trate all charge states for the intact ions. All identified species were accurate to
20 ppmwith external calibration. All experimentswere performed at least twice
to verify the findings.
Identification of BryR Active Site Acetylation
by LC FTICR-MS and LC ion Trap-MS
BryR (10 mM)was reactedwith acetyl-donor ACP (50 mM) and no acceptor ACP
in 75 mM HEPES (pH 7.5) buffer, 1 mM TCEP. TPCK trypsin (1 mg/ml; Pierce)
was added to a final 1:100 ratio. Samples were incubated at 37C overnight.
Twenty microliters of samples was injected onto a Jupiter C18 1 3 150 mm1098 Chemistry & Biology 17, 1092–1100, October 29, 2010 ª2010 Elsevier Ltd All rights rese300 mm column (Phenomenex) using an Agilent
1100 LC system with a flow rate of 75 ml/min and
a gradient of 2%–98% acetonitrile over 85 min.
Formic acid (0.1%) was added to the water and
acetonitrile solvents. A divert valve was utilized
for online desalting. The LC was coupled to an
FTICR MS (APEX-Q with Apollo II ion source and
actively shielded 7T magnet; Bruker Daltonics).
Data were gathered fromm/z 200–2000 in positive
ion mode. Electrospray was conducted at 2600 V
with four scans per spectrum utilizing 0.33 s
external ion accumulation in a hexapole and 4ICR cell fills prior to excitation and detection. Data were analyzed using
DECON2LC and VIPER (Pacific Northwest National Labs). The acetylated
active site peptide QACYSGTAGFQMAINFILSR (2219.050 Da expected) was
observed at 2219.045 Da representing a mass error of 2 ppm with external
calibration. The same LC conditions were coupled to an LTQ Deca XP iontrap
MS (Thermo). Online MS identified the same modified peptide, and online MS2
allowed for confirmation that the modification occurred on the active site
cysteine (Cys114) with the following fragment ions identified (Table 1). Data
were processed in Excaliber version 3.0 (Thermo).
Surface Plasmon Resonance Assays of BryR, ACPD, and ACPA
Sensor chips (CM-5) andHBS-Pbufferwerepurchased fromGEHealthcare Life
Sciences. SPR experiments were performed on a BIAcore 3000 instrument.
Running buffer for SPR was HBS-P+T (10 mM HEPES [pH 7.4], 0.15 M NaCl,
0.005% surfactant P20, 50 mM TCEP). The surface was prepared for immobili-
zation of BryR by activating with 70 ml of a fresh mixture of 0.2 M 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide (EDC)plus0.05MN-hydroxysuccinimide
at 10 ml/min. BryR diluted to 20 mM in 10 mM phosphate/citrate buffer (pH 5.5)
and loadedat 5ml/min (FigureS10). Typically, 1000–8000RUofBryRwas immo-
bilized. Activated carboxy groups were blocked with 1 M ethanolamine/HCl
(70 ml at 10 ml/min). The surface was regenerated with 10 ml of 50 mM NaOH,
1 M NaCl after immobilization and between ACP binding cycles. To measure
binding to BryR by SPR, solutions of ACPs in HBS-P+T were injected over the
prepared surface as well as an ethanolamine treated control flow cell at a flow
rate of 10 ml/min. Baseline subtraction was performed using a mock-treated
lane (activated with EDC/NHS and blocked with ethanolamine). Multiple injec-
tions (eight to ten concentrations) were tested in duplicate or triplicate.
Maximum testable concentrations for the ACPs were limited by their solubility.
Data analysis was carried out using BIAevaluation software (GE Healthcare
Life Sciences). Representative sensorgrams for four concentrations of apo-
JamF binding to BryR are shown in Figure S11. Nonlinear curve fitting of the
equilibrium binding response was carried out using GraphPad Prism software.
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